Cover Image
市場調查報告書

卡那凡氏症:開發中產品分析

Canavan Disease - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 361639
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
卡那凡氏症:開發中產品分析 Canavan Disease - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 25 Pages
簡介

本報告提供卡那凡氏症治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

卡那凡氏症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

卡那凡氏症:企業開發中的治療藥

卡那凡氏症:大學/機關研究中的治療藥

卡那凡氏症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

卡那凡氏症:企業開發中的產品

卡那凡氏症:大學/機關研究中的產品

卡那凡氏症的治療藥的開發企業

  • StemCells, Inc.
  • Turing Pharmaceuticals AG

卡那凡氏症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

卡那凡氏症:最近的開發平台趨勢

卡那凡氏症:暫停中的計劃

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9411IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Canavan Disease - Pipeline Review, H1 2017, provides an overview of the Canavan Disease (Central Nervous System) pipeline landscape.

Canavan disease is a gene-linked neurological disorder in which the brain degenerates into spongy tissue riddled with microscopic fluid-filled spaces. Cause includes a mutation in the gene which directs the production of the enzyme aspartoacylase (ASPA) allows the buildup of N-acetylaspartic acid (NAA) in the brain. The buildup of NAA causes damage to myelin. Symptoms include lack of motor development, feeding difficulties, abnormal muscle tone, and an abnormally large, poorly controlled head, paralysis, blindness, or hearing loss.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Canavan Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Canavan Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Canavan Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Canavan Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Canavan Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Canavan Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Canavan Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Canavan Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Canavan Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Canavan Disease (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Canavan Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Canavan Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Canavan Disease - Overview
  • Canavan Disease - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Canavan Disease - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Molecule Type
  • Canavan Disease - Companies Involved in Therapeutics Development
  • Pfizer Inc
  • Turing Pharmaceuticals AG
  • Canavan Disease - Drug Profiles
  • Gene Therapy 2 to Activate Aspartoacylase for Canavan Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Enzyme to Replace Aspartoacylase for Canavan Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TUR-007 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Canavan Disease - Dormant Projects
  • Canavan Disease - Discontinued Products
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Canavan Disease, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Canavan Disease - Pipeline by Pfizer Inc, H1 2017
  • Canavan Disease - Pipeline by Turing Pharmaceuticals AG, H1 2017
  • Canavan Disease - Dormant Projects, H1 2017
  • Canavan Disease - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Canavan Disease, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top